The firm’s revenue only fell by 14% for the entire year as part of better industry conditions in Q1 and Q2 2022.

Cryptocurrencies, Canaan, BTCRead More

You might also be interested in reading Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline.